Industrial Purity Specs and COA Analysis for (R)-3-Aminobutan-1-ol

• High Enantiomeric Excess: Guaranteed ee >99% for critical chiral synthesis applications.
• Verified COA Data: Comprehensive impurity profiles meeting ICH Q3 guidelines.
• Bulk Availability: Scalable supply chain managed by NINGBO INNO PHARMCHEM CO.,LTD.

In the landscape of modern pharmaceutical intermediates, the demand for high-fidelity chiral building blocks has never been more critical. (R)-3-Aminobutan-1-ol, identified by CAS Number 61477-40-5, serves as a pivotal precursor in the synthesis of antiviral agents and other complex organic molecules. For procurement officers and process chemists, understanding the Certificate of Analysis (COA) is not merely a regulatory formality but a fundamental step in ensuring reaction yield and final drug safety. This technical overview dissect the industrial purity specs required for bulk procurement.

Understanding Certificate of Analysis (COA) Parameters for (R)-3-Aminobutan-1-ol

A robust COA provides the chemical fingerprint necessary for quality assurance. When evaluating (3R)-3-Amino-1-butanol, the primary metric of concern is the assay purity, typically determined via Gas Chromatography (GC) or High-Performance Liquid Chromatography (HPLC). Industrial grade specifications generally demand an assay purity exceeding 98.0%, with many advanced synthesis routes requiring ≥99.0% to minimize downstream purification costs.

Beyond simple assay percentage, the COA must detail the enantiomeric excess (ee). Since this molecule is a chiral intermediate, the presence of the (S)-enantiomer is considered a critical impurity. Leading suppliers ensure that the optical purity is maintained throughout the supply chain. Furthermore, the COA should list residual solvents, heavy metals, and water content, adhering to strict limits defined by pharmacopeial standards. At NINGBO INNO PHARMCHEM CO.,LTD., every batch undergoes rigorous testing to ensure these parameters meet global pharmaceutical standards before shipment.

Key Physical and Chemical Identifiers

To ensure proper handling and regulatory compliance during logistics, buyers must verify the fundamental physical data against their internal safety databases. The molecular formula C4H11NO and molecular weight of 89.14 g/mol are standard, but transport classifications vary based on concentration and formulation. The material is often classified under UN 2734, Hazard Class 8, Packing Group II, indicating it is a corrosive liquid. This classification impacts storage requirements and shipping documentation.

Parameter	Specification	Test Method
CAS Number	61477-40-5	N/A
Molecular Formula	C4H11NO	N/A
Molecular Weight	89.14 g/mol	N/A
Assay (Purity)	≥ 98.0% (GC Area)	GC-MS / HPLC
Enantiomeric Excess	≥ 99.0% ee	Chiral HPLC
Water Content	≤ 0.5%	Karl Fischer
Transport Class	UN 2734 / Class 8 / PG II	DOT / IATA

Key Purity Metrics: Enantiomeric Excess, Assay, and Impurity Profiles

The value of (R)-3-Aminobutan-1-ol in medicinal chemistry lies in its stereochemistry. In antiviral synthesis, the wrong enantiomer can lead to inactive byproducts or, worse, toxic metabolites. Therefore, the industrial purity specification must prioritize enantiomeric excess over simple chemical assay. A batch with 99% chemical purity but only 90% ee is often unacceptable for GMP manufacturing.

Impurity profiles are equally vital. Process-related impurities, such as starting materials or reduction byproducts, must be quantified. Advanced analytical methods like GC-MS are employed to identify unknown peaks above the identification threshold (typically 0.10%). For bulk buyers, requesting a representative COA before contract finalization is standard practice. This ensures that the chiral building block integrates seamlessly into existing synthesis workflows without requiring additional recrystallization steps that reduce overall yield.

When sourcing these materials, understanding the origin of the purity is key. Buyers should inquire about the manufacturing process used to generate the intermediate. Whether derived via enzymatic resolution or asymmetric hydrogenation, the route dictates the impurity profile. A transparent supply chain provides data on potential genotoxic impurities, aligning with ICH M7 guidelines.

Compliance with ICH Guidelines for Pharmaceutical Intermediates

Regulatory compliance extends beyond the bottle label. Pharmaceutical intermediates destined for active pharmaceutical ingredient (API) synthesis must align with International Council for Harmonisation (ICH) guidelines. Specifically, ICH Q3A and Q3B dictate the reporting and identification thresholds for impurities in new drug substances. For a global manufacturer, adherence to these guidelines is non-negotiable.

Documentation such as the HSN Code 29052900 facilitates correct customs classification, preventing delays at international borders. Additionally, safety data sheets (SDS) must reflect the correct signal word, typically "Warning" for this grade, along with appropriate hazard pictograms. Storage conditions also play a role in maintaining purity over time. Recommendations usually include storing under inert gas (nitrogen or argon) at controlled room temperature to prevent oxidation or moisture uptake, which can degrade the amine functionality.

Bulk Procurement and Supply Chain Stability

Securing a reliable supply of (3R)-3-aminobutan-1-ol requires a partner capable of scaling production without compromising quality. Fluctuations in bulk price are often tied to raw material availability and energy costs associated with distillation and purification. A stable partner offers long-term contracts that lock in specifications and pricing, mitigating supply chain risks.

Procurement teams should evaluate suppliers based on their capacity to provide consistent COA data across multiple batches. Batch-to-batch variability is a significant risk factor in process chemistry. By partnering with an established entity like NINGBO INNO PHARMCHEM CO.,LTD., clients gain access to a supply chain optimized for technical support and logistical efficiency. This ensures that critical project timelines for antiviral drug development are met without interruption due to material shortages or quality failures.

In conclusion, the technical specifications for (R)-3-Aminobutan-1-ol demand rigorous attention to stereochemistry, assay purity, and regulatory documentation. By prioritizing verified COA parameters and compliant logistics, pharmaceutical manufacturers can ensure the integrity of their final therapeutic products.